Azimuth Capital Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Azimuth Capital Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,000	Closed	-$60.3K	–	317
2026 Q1	$60.3K	Hold	22,000	–	–	﹤0.01%	298
2025 Q4	$81.4K	Hold	22,000	–	–	﹤0.01%	305
2025 Q3	$58.3K	Hold	22,000	–	–	﹤0.01%	296
2025 Q2	$21.7K	Hold	22,000	–	–	﹤0.01%	297
2025 Q1	$31.7K	Hold	22,000	–	–	﹤0.01%	300
2024 Q4	$48.4K	Hold	22,000	–	–	﹤0.01%	298
2024 Q3	$36.3K	Hold	22,000	–	–	﹤0.01%	301
2024 Q2	$48.8K	Hold	22,000	–	–	﹤0.01%	302
2024 Q1	$59K	Hold	22,000	–	–	﹤0.01%	306
2023 Q4	$65.8K	Buy	+22,000	New	+$28.5K	﹤0.01%	300

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Azimuth Capital Investment Management's ESPR Position: Q2 2026 in Review

Azimuth Capital Investment Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 22,000 shares — an estimated $60.3K sold.

Azimuth Capital Investment Management first reported a position in ESPR in Q4 2023 and held it in 10 quarters. The position peaked at $81.4K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Azimuth Capital Investment Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
Azimuth Capital Investment Management sold 22,000 Esperion Therapeutics shares in Q2 2026, an estimated $60.3K.
Azimuth Capital Investment Management first reported a position in Esperion Therapeutics in Q4 2023 and held it in 10 quarters.
Azimuth Capital Investment Management's Esperion Therapeutics position peaked at $81.4K in Q4 2025.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Azimuth Capital Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.